Greta Slappy
Family · Sylvester, GANPI 1447644265
Payments from drug & device makers
Across 94 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$273
- Cardiovascular Systems Inc.$209
- Novo Nordisk$168
- Bard Peripheral Vascular, Inc.$133
- Organogenesis Inc.$122
- Johnson & Johnson$103
- plus $920 from 21 others
What the payments were for
- Food & beverage$1,928100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $273 |
| Cardiovascular Systems Inc. | 11 | $209 |
| Novo Nordisk | 9 | $168 |
| Bard Peripheral Vascular, Inc. | 3 | $133 |
| Organogenesis Inc. | 1 | $122 |
| Johnson & Johnson | 8 | $103 |
| AbbVie | 5 | $96 |
| Abbott | 4 | $91 |
| Sumitomo Pharma America, Inc. | 1 | $84 |
| Bayer | 4 | $74 |
| Shield Therapeutics Inc | 3 | $47 |
| Paratek Pharmaceuticals, Inc. | 3 | $45 |
| Inari Medical, Inc. | 3 | $44 |
| Lemaitre Vascular, Inc. | 2 | $43 |
| GSK | 2 | $42 |
| Exact Sciences | 2 | $41 |
| Pfizer | 2 | $41 |
| Astellas Pharma US Inc | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| AstraZeneca | 2 | $36 |
| Medtronic | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Dexcom, Inc. | 1 | $25 |
| Cordis US CORP. | 1 | $25 |
| Amgen | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $15 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PuraPly$122
How this compares
$1,928 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 164 | $154,735 |
| MounjaroTirzepatide | 99 | $108,246 |
| JardianceEmpagliflozin | 83 | $92,551 |
| EliquisApixaban | 94 | $89,848 |
| OzempicSemaglutide | 82 | $87,954 |
| TrulicityDulaglutide | 35 | $34,710 |
| LinzessLinaclotide | 35 | $26,620 |
| XareltoRivaroxaban | 27 | $25,503 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,707 |
| Spiriva RespimatTiotropium Bromide | 11 | $11,210 |
| DapagliflozinDapagliflozin Propanediol | 16 | $8,912 |
| GemtesaVibegron | 12 | $8,838 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $8,430 |
| KerendiaFinerenone | 12 | $8,147 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $8,074 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $36 | $154,735164 claims |
| Lilly USA, LLCMounjaro, Trulicity | $273 | $142,956134 claims |
| PfizerEliquis | $41 | $89,84894 claims |
| Novo NordiskOzempic | $168 | $87,95482 claims |
| AbbVieLinzess, Synthroid | $96 | $29,23266 claims |
| Johnson & JohnsonXarelto | $103 | $25,50327 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $42 | $22,78136 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $84 | $8,83812 claims |
| BayerKerendia | $74 | $8,14712 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $7,38512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.
Other family in Sylvester
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.